/

KAPA

Kairos Pharma, Ltd.Open

0.7701−0.06 −7.07%USD

NYSE American · as of Oct 14, 11:04 ET

Open

0.8038

Prev close

0.8287

Day range

0.75040.7950

52-week range

0.74009.17

Volume

160.45K0.26×

Mkt cap

2.61M

P/E ttm

—

Fwd P/E

-0.16

EPS ttm

-1.96

Div yield

0.00%

Earnings

—

From 52w high

−91.60%

Price Chart

Yahoo Finance · delayed

KAPAOct 14, 2026O 0.8038H 0.7950L 0.7504C 0.7701−0.0589 (−7.10%)Vol 160.45K

SMA 501.7670
SMA 2003.3504

1Y change −90.91% since Oct 13, 2025 close522 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

KAPA Kairos Pharma, Ltd. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −11.48%
1 month: −58.15%
3 months: −65.40%
6 months: −81.66%
Year to date: −84.51%
1 year: −91.47%

Valuation & ownership

Market cap: 2.61M
Enterprise value: 179.33K
P/E (ttm): —
Forward P/E: -0.16
PEG ratio: —
Price / book: 0.56
Price / sales (ttm): —
EV / EBITDA: -0.03
EPS (ttm): -1.96
EPS (forward): -4.69
Beta (5y monthly): 1.44
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 3.39M
Float: 2.25M
Short % of float: 4.70%
Short ratio (days): 1.13
Held by insiders: 33.61%
Held by institutions: 7.82%
Avg volume (3m): 619.45K
50-day average: 1.80
200-day average: 3.37
52-week change: −91.47%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): oversold 20.6
vs 50-day SMA: −56.42%
vs 200-day SMA: −77.01%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 25.14%
Realised vol (20d, ann.): 156.2%
From 52-week high: −91.60%
From 52-week low: +4.07%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

49.00

+6,263.13% implied

Low 14.00Median 49.00High 84.00

Recommendation trend

Now2 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →

DES

About Kairos Pharma, Ltd.

Yahoo Finance profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist designed to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, as well as a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions for the treatment of autoimmune disease; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor that targets tumor cells in RelA/p65 biomarker-positive solid tumors for the treatment of triple-negative breast cancer; KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, reversing tumor associated macrophage inhibition that blocks the IL4/IL13 cytokine immune receptors for the treatment of triple-negative breast cancer; and ENV 205, an antibody fragment that targets mitochondrial DNA for the treatment of prostate cancer. The company also develops ENV-105 (carotuximab). The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 1

SEAS

Seasonality · KAPA

2024–2026 · monthly returns

Strongest month Aug +50.00%Weakest month May −24.78%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-6.5	-8.7	-7.8	1.1	-9.9	-24.6	-20.3	-21.6	-2.4	-53.0			−84.5%
2025	-5.9	-16.8	-21.3	-13.4	-24.8	16.2	26.9	50.0	-13.3	-3.4	-26.2	-14.9	−53.3%
2024										-16.6	17.6	-1.3	−3.2%

INSD

Insider Activity · KAPA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Oct 7, 2025	Singhvi RahulDirector	—	19.1K	—
Oct 7, 2025	Yu John SChief Executive Officer	—	190.8K	—
Oct 7, 2025	Keyoung Hansoo MichaelDirector	—	29.1K	—
Oct 7, 2025	Samuelson DougChief Financial Officer	—	152.7K	—
Oct 7, 2025	Bhowmick Neil Ph.D.Officer	—	171.8K	—
Oct 7, 2025	Bae Hyun W. M.D.Director	—	29.1K	—
Oct 7, 2025	Murali Ramachandran Ph.D.Officer	—	152.7K	—
Dec 30, 2024	Yu John SChief Executive Officer	—	14K	—
Dec 30, 2024	Bhowmick Neil Ph.D.Officer	—	14K	—
Dec 30, 2024	Murali Ramachandran Ph.D.Officer	—	14K	—
Nov 24, 2024	Murali Ramachandran Ph.D.Officer	Purchase at price 1.59 per share.	200	$318
Nov 21, 2024	Samuelson DougChief Financial Officer	Purchase at price 1.50 per share.	2.5K	$3.75K
Nov 19, 2024	Yu John SChief Executive Officer	Purchase at price 1.44 per share.	4K	$5.76K

KAPA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

KAPA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Kairos Pharma, Ltd.

Seasonality · KAPA

Insider Activity · KAPA

Congress Trades · KAPA

Investors Holding KAPA

Investors Holding KAPA

Congress Trades · KAPA

Insider Activity · KAPA

Seasonality · KAPA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Kairos Pharma, Ltd.

Earnings & Dividends

News